Previous Close | 0.8050 |
Open | 0.7500 |
Bid | 0.7300 x 800 |
Ask | 0.7850 x 1000 |
Day's Range | 0.7300 - 0.7600 |
52 Week Range | 0.3800 - 4.0500 |
Volume | |
Avg. Volume | 38,375 |
Market Cap | 5.74M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announce
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP. BROOMFIELD, CO , Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is lev